The best ophthalmology research papers of 2020


December 31, 2020

3 minutes to read

Biography: Singh is a surgeon at the Cole Eye Institute, Cleveland Clinic and an associate professor of ophthalmology at Lerner College of Medicine in Cleveland Ohio. He is also currently the Medical Director of Informatics at the Cleveland Clinic.

Disclosures: Singh reports that he is a consultant for Zeiss, Novartis, Regeneron, Genentech and Alcon and receives a grant from Apellis and Graybug.

We have not been able to process your request. Please try again later. If you continue to experience this problem, please contact [email protected]

Despite the COVID-19 pandemic, ophthalmology research has continued at an exciting rate.

Each year it is amazing to see the number of submissions received by the journal Ophthalmic Surgery, Lasers and Retina Imaging, And this year was no exception. To wrap up this year, I’m going through the magazine’s five most popular articles, determined by the number of downloads and clicks. And despite the intense competition, please submit your articles to us for review in 2021 here.

# 5 – Pachychoroid Disease in the Practical Retina, April 2020.

Rishi P. Singh

K. Bailey Freund in the Practical Retina section integrates the results of technological advances to summarize the latest discoveries in pachychoroid disease. No one has done more to advance our understanding of this medical condition than Dr. Freund. Briefly, the diagnosis of pachychoroid was established by the following characteristics:

  1. Increased thickness of the choroid co-localizing with areas of fundus abnormalities, which may be focal or diffuse;
  2. Clinically visible dilated choroidal vessels or reduced fundus paving in the eyes with diffuse choroid thickening;
  3. Attenuation of the internal choroid in areas of pathology of the fundus;
  4. ICGA choroidal hyperpermeability and reduced internal choroidal flow signal, as shown by optical coherence tomography angiography;
  5. Pachyvessels (dilated Haller’s layer veins) often co-localizing with the overlying disease manifestations; and
  6. RPE drusenoid lesions (recently renamed “pachydrusen” by Spaide)

# 4 – Private etranquility gI am plocal network asd wHello It shold on mto land to yous, August 2020

Veeral sheth, MD, MBA, and Dilsher dhoot, MD, in another Practical Retina column, discuss rapid acquisitions of private capital in ophthalmology and retina practices. While there are benefits to private equity, including efficiencies through economies of scale, negotiating better contracts, and standardizing practices that lead to better and more efficient patient care, there is certainly another aspect to consider. However, given current market forces, like COVID-19 and possible pricing of most-favored nation drugs on the horizon, Drs. Sheth and Dhoot confirm that the fate of these private equity deals in the next 10 years is uncertain. As the first wave of private equity firms begin to pull back, they predict a shift from a more traditional hospital-doctor alignment to other types of integration such as selling those initial investments to big payers. health care.

# 3 Long-tuh vision oresults in ppatients wwith DME and a Iimitated early anti-VEGF rresponse, April 2020

I wrote the third most popular post this year in OSLI Retina, which examines those with a limited early response to anti-VEGF therapy for diabetic macular edema. A common misconception in the retina is that a limited early response (within the first three injections) has a poor long-term visual prognosis. This was initially verified with treatment as needed as part of the Protocol I study by the DRCR Retina Network. However, we hypothesized that consistent treatment would overcome these limited responders. We retrospectively evaluated the RISE and RIDE data from the pivotal ranibizumab studies for DME to assess this concept and found that although Protocol I had patients who developed ‘swim lanes’, where a response limited early predicted long-term outcome, RISE and RIDE demonstrated consistent improvement in vision with a mandatory treatment approach.

# 2 – Social vsmost of blindness Dthanks to AMD and Ddiabetic retinopathy in the United States in 2020, April 2020

Andrew Moshfeghi, MD, MBA, estimated the social cost of blindness in the United States due to age-related exudative macular degeneration, diabetic macular edema, and proliferative diabetic retinopathy in 2020. This article, also recognized as a premier abstract plan at Retina World Congress, found the costs associated with these diseases combined states resulted in a total cost to society of $ 20 billion in 2020 and is estimated to triple by 2050. Interestingly, though These costs are substantial, a minority of the burden has been attributed to direct health care costs, such as drug and insurance costs.

# 1 – SAFER-ROP: Update protocol for anti-VEGF Iinjections for retinopathy prematurityjuly 2020

And the best article of OSLI Retina 2020 was the SAFER-ROP protocol for anti-VEGF injections for retinopathy of prematurity. In this article by Kinley D. Beck, MD, and colleagues, they propose the acronym SAFER to describe best practice when treating these patients. SAFER stands for (S) short needle (4mm length), (A) antiseptic / antibiotic (5% to 10% topical betadine), (F) follow-up (48 hours to 72 hours after injection), (E) extra attention to detail (clean environment, injection site 0.75mm to 1.0mm posterior to limbus) and (R) echeck (1 to 2 weeks after injection and until mature or laser vascularity) . With the use of this protocol, the authors hope to minimize complications that may arise with ROP following anti-VEGF treatment.

I wish you all a happy, healthy and prosperous New Year!

Source link


About Author

Comments are closed.